Prevention as an Asset Class
Make Prevention Investable
Prevention fails when incentives arrive too late. EDEN aligns four timelines so prevention pays first.
Reach patients fast. Retain them long enough. Report results before budgets reset. Reimburse within investor horizons.
Digital Diabetes Screening, Switzerland
- -Reach: Digital biomarkers detect risk 2-3 years earlier
- -Report: Results visible within payer budget cycles
- -Reimburse: Breakeven Year 4 fits investor horizons
In collaboration with
The 5 Pillars of Modern Healthcare
Medicine is shifting from reactive to proactive. EDEN finds where that shift creates investment opportunities.
Prevention
Stop disease before it starts. Cheaper than treating it later.
Prediction
Spot risk before symptoms appear. Intervene when it is cheap.
Personalization
Tailor treatment to the individual. One-size-fits-all wastes money.
Participation
Get patients to actually use it. The best product fails if nobody adopts it.
Profitability
Make the numbers work. Good medicine that loses money does not scale.
The 4R Framework
Prevention is a time-value problem. Each actor discounts differently: patients discount daily effort, payers discount long-term savings, investors discount post-exit outcomes.
Prevention fails when timelines are wrong. It succeeds when timelines are designed right.
Four timelines determine whether prevention can be adopted, integrated, and financed:
How fast can we find risk before it becomes costly?
How long until users convert engagement into outcomes?
How quickly can we show results before budgets reset?
When does payoff appear relative to investor horizons?
How fast can we find risk and engage before it becomes costly?
How long until users convert engagement into outcomes?
How quickly can we report outcomes before budgets reset?
When does payoff appear relative to investor horizons?
If any timeline is misaligned, the innovation dies - even with perfect clinical evidence.
Prevention Market Opportunity Map
Not all preventive ideas are created equal — mapped Time-Value arbitrage
| Company | Description | Investors | Deal | Year | EDEN Insight |
|---|---|---|---|---|---|
| Omada Health | Digital pre-diabetes reversal | Cigna Ventures, a16z, Kaiser Permanente Ventures | $50M | 2022 | Model ROI < 5 yrs for CGM + coaching |
| Hinge Health | MSK programs, 2yr payback | Tiger Global, Coatue, Insight Partners | $600M | 2022 | Quantify avoided ER/surgery costs |
| Virta Health | Self-insured corporates | Sequoia, Venrock, Cigna Ventures | $65M | 2022 | Target stable workforce contracts |
| Company | Description | Investors | Deal | Year | EDEN Insight |
|---|---|---|---|---|---|
| Aledade | Physician ACO network | Venrock, OMERS Growth, Meritech | $260M | 2023 | Savings-share ROI modeling |
| Doctor Anywhere | Primary-care DHTs (Singapore) | Novo Holdings, Asia Partners | $88M | 2022 | Prevention ROI in capitated systems |
| Oviva | Digital nutrition (EU) | Temasek, Sofina, MTIP | $80M | 2022 | National reimbursement frameworks |
| Company | Description | Investors | Deal | Year | EDEN Insight |
|---|---|---|---|---|---|
| CVS Health + Aetna | Pharmacy + payer merger | Merger | $69B | 2018 | Synergy ROI in integrated care |
| Cityblock Health | Medicaid super-utilizers | Alphabet GV, Emerson, Tiger Global | $400M | 2021 | ROI in underserved markets |
| Propeller Health | COPD monitoring | Acquired by ResMed | $225M | 2018 | Hospital-avoidance value capture |
| Company | Description | Investors | Deal | Year | EDEN Insight |
|---|---|---|---|---|---|
| Levels Health | Consumer CGM | a16z, General Catalyst | $44M | 2023 | CGM data to short-term ROI |
| Biofourmis | Predictive analytics | SoftBank Vision Fund 2 | $300M | 2022 | 90-day risk scores to contracts |
| Huma | Voice/gait monitoring | Leaps by Bayer, SoftBank, Sony | $130M | 2022 | Outcome-based payments via RWD |
| Toku Eyes | AI retinal screening | Icehouse Ventures, NZ Gov Fund | $8M | 2023 | Diagnostic AI in preventive contracts |
| Company | Description | Investors | Deal | Year | EDEN Insight |
|---|---|---|---|---|---|
| Ro | Sexual health, weight loss | General Catalyst, FirstMark | $150M | 2021 | DTC pricing for cash flows |
| Hims & Hers | Hair loss, sexual wellness | Forerunner, Redpoint, IVP | $200M | 2021 | Low-friction consumer model |
| Headspace Health | Mental health (merger) | Blackstone Growth, KKR | $3B | 2021 | B2B2C employer programs |
| Lyra Health | Employer-paid therapy | Accel, Dragoneer | $235M | 2023 | Employer WTP and retention ROI |
| Altoida | Digital cognition biomarkers | M Ventures (Merck), Evidation | $20M | 2022 | Preventive ROI in neurodegeneration |
EDEN quantifies which interventions deliver measurable ROI < 5 years, under which payment models, with which stakeholder incentive alignment — translating fragmented prevention signals into Prevention as an Asset Class.
EDEN: Your Arbitrage Engine
Three analytic modules reveal what the system must do to make prevention work.
System-Fit Analysis
How payers discount savings, providers discount friction, patients discount future health.
Defines feasible Reach and Retain timelines.
HTA & Clinical Modelling
Translates clinical pathways into discounted health outcomes and system-adjusted QALYs.
When will Report happen - compatible with budget cycles?
Financial Modelling
ROI timelines, breakeven years, valuation curves, investor discount rates. Auditable DCF models.
When does Reimburse happen - inside investor horizon?
Start Finding Opportunities
Weekly signals on prevention investments where 4R timelines align. Transparent models you can verify.
How It Works
EDEN learns from real-world health, market, and policy data to reveal which prevention models create measurable returns—and why.
From raw data to investment-ready signals
- OECD, World Bank & WHO – macroeconomic and population metrics
- PitchBook & Crunchbase – venture funding intelligence
- PubMed – scientific and clinical studies
- FDA Database – regulatory approvals
- IP Databases (USPTO, Espacenet) – early technology signals
- Hospital Statistics – national healthcare and cost data
- HTA Databases (Swiss HTA, NICE) – reimbursement benchmarks
Digital Diabetes Screening, Switzerland
How EDEN redesigns each timeline to make prevention investable
4R Breakdown
Reach
Digital biomarkers cut diagnostic delay by 2-3 years.
Retain
Tailored nudges keep users engaged until metabolic change occurs.
Report
Glucose improvements create evidence within payer budget cycles.
Reimburse
Year 4 breakeven fits 3-7 year investor horizons.
Not just a cost-effectiveness claim. A temporal blueprint for system integration.
Bottom Line
Can a consumer diabetes app work as an investment in Switzerland? Yes, when 4R timelines align.
The upside: Regulatory and clinical hurdles keep competitors out. Pure software cannot copy the clearances and evidence you build.
Moat Duration
Different prevention investments have different competitive windows:
Short
Examples: Wellness apps, meditation apps
Easy to copy. Pure software. No lasting advantage.
Medium
Examples: Glucose monitors, AI diagnostics with proprietary data
Requires hardware, regulatory approval, or clinical proof.
This case fits here
Long
Examples: Integrated health systems, employer clinics
Structural positions. Not typical investment targets.
EDEN Analysis
Does This Work in Switzerland?
Working For You
Consumers ready to pay. Technology exists. Success measurable.
Working Against You
Insurance coverage unclear. Government support weak. Hospital integration difficult.
Will People Pay?
Early adopters pay out of pocket. Scale requires employer or insurer contracts.
Do the Numbers Work?
Breakeven Year 4 with 18,446 users (under 0.5% of Swiss adults). At 30,000 users by Year 6, valuation CHF 0.94-3.2M.
Long-term success requires B2B insurer contracts.
Key Numbers
| Metric | Value | Meaning |
|---|---|---|
| Time to Breakeven | Year 4 | Fits investor horizons |
| Market Share Required | Under 0.5% | Achievable in Swiss market |
| Valuation at 30k Users | CHF 0.94-3.2M | Based on risk tolerance |
| Scale Strategy | B2B | Insurer contracts for sustainable Retain |
Market Context
Market Size 2030
15-20% annual growth
EDEN Filter Accuracy
Screens misaligned timelines
Lead Time
Before market consensus
Sample 4R outputs (2024 data). Not investment advice.
Why It Works
Peer-reviewed methods translating health innovation into investment decisions
Every paper summary includes actionable insights for investors, payers, and founders—no academic jargon, just investable intelligence
Wasu Mekniran, Tobias Kowatsch
Biomedical Engineering Conference - Portugal
💡 Investor takeaway:Use EDEN's thresholds instead of biotech heuristics to avoid overpaying for DHT optionality.
What This Unlocks
Investors:
Demonstrates scalable AI approach to market analysis and stakeholder mapping for prevention ventures
Payers:
Provides framework for identifying aligned partners in prevention ecosystem
Founders:
Offers methodology to map competitive landscape and identify strategic partners
Wasu Mekniran
💡 Investor takeaway:Use EDEN's thresholds instead of biotech heuristics to avoid overpaying for DHT optionality.
What This Unlocks
Investors:
Reveals why DHT investments require different evaluation criteria than traditional biotech
Payers:
Explains structural challenges in DHT reimbursement compared to pharmaceutical products
Founders:
Identifies four strategic positioning options for DHT competitive advantage
Wasu Mekniran, Lukasz Paciorkowski, Iwona Cymerman, Rafal Pawlowski
4th Swiss-Polish Economic and Technology Forum
💡 Investor takeaway:AI-first development reduces costs by 70%—prioritize companies with AI infrastructure.
What This Unlocks
Investors:
Quantifies cost savings and efficiency gains from AI adoption in drug development
Payers:
Shows potential for lower drug costs through AI-enabled development efficiency
Founders:
Demonstrates competitive advantage of AI-first development approach
Wasu Mekniran, Mia Jovanova, Tobias Kowatsch
Swiss Society of Endocrinology and Diabetes 2024
💡 Investor takeaway:Three contract models identified—target data-driven lifestyle change for fastest ROI.
What This Unlocks
Investors:
Maps value flows and revenue opportunities in diabetes prevention ecosystem
Payers:
Identifies three contract models for diabetes prevention reimbursement
Founders:
Reveals critical partnerships needed to align incentives for market entry
Wasu Mekniran, Jan-Niklas Kramer, Tobias Kowatsch
Biomedical Engineering Conference - Italy
💡 Investor takeaway:NCDs and stigmatized conditions have highest payer appeal—prioritize these segments.
What This Unlocks
Investors:
Reveals insurer decision criteria and three strategic pathways for DHT partnerships
Payers:
Outlines three business model options for insurers entering prevention market
Founders:
Identifies which DHT categories have highest payer appeal and why
Wasu Mekniran, Tobias Kowatsch
Biomedical Engineering Conference - Portugal
💡 Investor takeaway:B2B2C models outperform D2C—prioritize employer partnerships for scale.
What This Unlocks
Investors:
Identifies proven business model patterns from $1.73B in successful DHT funding
Payers:
Shows why B2B2C models outperform direct-to-consumer in prevention
Founders:
Provides blueprint for scalable business model design in longevity space
Wasu Mekniran, Odile-Florence Giger, Elgar Fleisch, Tobias Kowatsch, Mia Jovanova
SWU Biomedical Engineering Dept.
💡 Investor takeaway:Five strategies to bridge academic-community gap—target underserved niches for market entry.
What This Unlocks
Investors:
Maps global longevity ecosystem to identify underserved niches and partnership opportunities
Payers:
Reveals alignment gaps between research and community needs for prevention programs
Founders:
Identifies five strategies to bridge academic-community gap for market validation
Wasu Mekniran, Research Team
NUS Healthy Longevity Academy
💡 Investor takeaway:Consumer WTP data coming Q3 2025—early insights available on request.
What This Unlocks
Investors:
Will reveal consumer willingness to pay for longevity interventions
Payers:
Will show population health priorities for prevention program design
Founders:
Will identify consumer segments most receptive to longevity products
Research With Us?
We build the tools that turn prevention into an investable asset class
Wasu Mekniran
Researcher, ETH Zurich & HSG | Healthcare Financing & Digital Health
We are building the infrastructure to make prevention investable. We combine health economics with financial modeling to translate clinical outcomes into investment decisions.
"The future of healthcare is prevention-first."
Market fit + adoption thresholds + ROI modeling = pricing longevity as an asset.
Ready to explore prevention as your next investment opportunity?